SCHEMBL2535431

SCHEMBL2535431

O=C(O)CCc1cc(-c2ccccc2)ccc1OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 8/20 0.64
PTGER3 P43115 8/20 0.64
PTGER1 P34995 7/20 0.64
PTGER2 P43116 7/20 0.64
FFAR1 O14842 6/20 0.58
FFAR4 Q5NUL3 3/20 0.58
AKR1B1 P15121 1/20 0.56
CFD P00746 1/20 0.53
PLG P00747 1/20 0.53
PLAU P00749 1/20 0.53
F11 P03951 1/20 0.53
KLKB1 P03952 1/20 0.53
F7 P08709 1/20 0.53
TPSB2 P20231 1/20 0.53
THRA P10827 1/20 0.50
THRB P10828 1/20 0.50
MRGPRX4 Q96LA9 1/20 0.50
S1PR1 P21453 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2531052 0.89 PTGER4 (0.58) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL2534023 0.88 PTGER4 (0.55) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL2534776 0.87 FFAR1 (0.56) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL2532590 0.86 FFAR1 (0.58) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL2537526 0.86 FFAR1 (0.58) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL17413725 0.85 PTGER4 (0.67) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL2532655 0.85 PTGER4 (0.61) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL2538767 0.85 PTGER4 (0.54) PTGER4PTGER3PTGER1PTGER2FFAR4
SCHEMBL11312296 0.84 PTGER4 (0.65) PTGER4PTGER3PTGER1PTGER2FFAR1
SCHEMBL16294058 0.83 PTGER1 (0.64) PTGER4PTGER3PTGER1PTGER2FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044236-B2 Inhibitors against plasminogen activator inhibitor-1 (PAI-1); anticoagulants; 2-(aryl or aralkyloxy-)-5-(aryl)phenyl}acetic acid (or derivatives of propionic acid, propenoic acid, N-oxamic acid or 1H-tetrazol-5-yl); occlusion, stenosis; low molecular weight; gene expression inhibition INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2011-10-25 US disclosed
EP-2080751-A1 CARBOXYLIC ACID DERIVATIVE Institute of Medicinal Molecular Design, Inc. (JP) 2009-07-22 EP disclosed
US-20080275116-A1 Carboxilic acid derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275116-A1 Carboxilic acid derivatives SERPINE1, CTRL, SERPINC1 PTGER4 3046/4885PTGER3 2505/4885PTGER1 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.